SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq:XNPT) announced today that it has initiated separate Phase 2 clinical trials of XP19986 in patients with gastroesophageal reflux disease, or GERD, and in spinal cord injury patients with spasticity. In addition, XenoPort announced the initiation of the first clinical trial of XP21279, a drug candidate designed to treat Parkinson’s disease.
